Intellia Therapeutics Inc Sustainability Reports
Intellia Therapeutics, Inc. is a clinical-stage genome editing company focused on developing curative therapeutics using the CRISPR/Cas9 system. The company designs both in vivo treatments delivered directly to target tissues and ex vivo therapies using engineered human cells.
Sector: Professional & technical services
Country: United States
Exchange: Nasdaq
LEI: 5493002T5BCPE5DZC723
FIGI: BBG007KC7PC9
11 reports from 2017 to 2025
